Kimberly Manhard
Directeur/Membre du Conseil chez INHIBRX, INC.
Profil
Kimberly J.
Manhard currently works at Inhibrx, Inc., as Independent Director from 2020, Shoreline Biosciences, Inc., as Director from 2021, Toragen, Inc., as Director from 2020, ACADIA Pharmaceuticals, Inc., as Senior VP-Global Strategic Planning & Execution from 2024, and The Fleet Science Center, as Trustee.
Ms. Manhard also formerly worked at Ardea Biosciences, Inc., as Director & Corporate Compliance Officer from 2009 to 2016, Heron Therapeutics, Inc., as Executive VP-Drug Development in 2023, Bristol Myers Squibb Co., as Head-Regulatory Affairs, Eli Lilly & Co., as Principal, Exelixis, Inc., as Vice President-Regulatory Affairs from 2002 to 2003, Agouron Global Commercial Operations, as Head-Regulatory Affairs, and G.H.
Besselaar Associates, as Principal.
Ms. Manhard received her undergraduate degree from the University of Florida.
Postes actifs de Kimberly Manhard
| Sociétés | Poste | Début |
|---|---|---|
| INHIBRX, INC. | Directeur/Membre du Conseil | 01/06/2020 |
| ACADIA PHARMACEUTICALS INC. | Corporate Officer/Principal | 30/01/2024 |
| Fleet Science Center | Directeur/Membre du Conseil | - |
Shoreline Biosciences, Inc.
 Shoreline Biosciences, Inc. BiotechnologyHealth Technology Shoreline Biosciences, Inc. engages in biotechnology business activities. The company is headquartered in La Jolla, CA. | Directeur/Membre du Conseil | 19/05/2021 |
Toragen, Inc.
 Toragen, Inc. BiotechnologyHealth Technology Toragen, Inc. is a clinical-stage biotechnology company that is focused on developing treatments for HPV-induced cancers, starting with head and neck cancer. Toragen is based in San Diego, CA. The company is targeting the root cause of virally induced cancers. The company was founded by Andrew Sharabi and the CEO is Sandra I. Coufal. | Directeur/Membre du Conseil | 01/05/2020 |
Anciens postes connus de Kimberly Manhard
| Sociétés | Poste | Fin |
|---|---|---|
| HERON THERAPEUTICS, INC. | Directeur/Membre du Conseil | 21/02/2023 |
Ardea Biosciences, Inc.
 Ardea Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ardea Biosciences, Inc. is a biotechnology company which is focused on the development of small-molecule therapeutics for the treatment of serious diseases. The company was founded in January 1994 and is headquartered in Wilmington, DE. | Directeur des opérations | 23/06/2009 |
| EXELIXIS, INC. | Conseiller Juridique Général | 01/01/2003 |
| G.H. Besselaar Associates | Corporate Officer/Principal | - |
| ░░░ ░░░░░ ░░░ ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formation de Kimberly Manhard
| University of Florida | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 6 |
|---|---|
| HERON THERAPEUTICS, INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| EXELIXIS, INC. | Health Technology |
| ACADIA PHARMACEUTICALS INC. | Health Technology |
| INHIBRX, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Ardea Biosciences, Inc.
Ardea Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ardea Biosciences, Inc. is a biotechnology company which is focused on the development of small-molecule therapeutics for the treatment of serious diseases. The company was founded in January 1994 and is headquartered in Wilmington, DE. | Health Technology |
| Agouron Global Commercial Operations | |
| G.H. Besselaar Associates | |
Shoreline Biosciences, Inc.
Shoreline Biosciences, Inc. BiotechnologyHealth Technology Shoreline Biosciences, Inc. engages in biotechnology business activities. The company is headquartered in La Jolla, CA. | Health Technology |
| Fleet Science Center | |
Toragen, Inc.
Toragen, Inc. BiotechnologyHealth Technology Toragen, Inc. is a clinical-stage biotechnology company that is focused on developing treatments for HPV-induced cancers, starting with head and neck cancer. Toragen is based in San Diego, CA. The company is targeting the root cause of virally induced cancers. The company was founded by Andrew Sharabi and the CEO is Sandra I. Coufal. | Health Technology |
